Cardiol Therapeutics Income Statement (2021-2022) | CRDL

Income Statement Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022
Revenue & cost
Revenue -7.10M-5.23M-8.07M-10.39M-7.73M-7.24M-10.14M
Operating items
Research & Development 2.12M1.69M2.06M2.80M3.04M3.46M3.90M
Share-based Compensation (IS) 0.15M0.28M0.30M
Selling, General & Administrative 4.98M3.60M6.01M7.59M4.69M3.78M6.23M
Operating Expenses 7.10M5.29M8.07M10.39M7.73M7.24M10.14M
Non-operating items
Non Operating Investment Income -1.68M0.68M1.32M
Interest & Investment Income 0.01M0.02M0.03M0.02M0.06M0.15M0.30M
Other Non Operating Income 0.04M-0.13M0.10M1.49M-1.10M1.33M2.28M
Additional items
Shares Outstanding (Weighted Average) 42.95M42.95M44.01M61.92M61.93M61.94M
EBITDA -7.04M-5.34M-7.87M-4.96M-7.07M-5.09M-6.11M